SAINT LOUIS, MO – April 16, 2014 – Sigma-Aldrich Corporation (NASDAQ: SIAL) today announced that the Cerilliant® brand within its Applied Diagnostics and Testing Business Unit introduced four new Certified Spiking Solutions® of the corticosteroids pregnenolone, 17α-hydroxypregnenolone, cortisone, and 11-deoxycorticosterone at concentrations of 100 µg/mL in methanol.

These new solution-based Certified Reference Materials are suitable for preparation of calibrators, controls, and linearity standards in clinical and diagnostic labs as well as hospitals and research settings which require the highest accuracy of results in applications ranging from diagnostic testing and clinical chemistry to endocrinology and neonatal screening. The stable quantitative solution format of Cerilliant’s Spiking Solutions® offers the laboratory benefits such as increased efficiency of labor and While the analysis of hormones and other small molecules for neonatal screening by LC-MS/MS is well established, other clinical applications are rapidly emerging. Pain management clinics, for example, are increasingly using LC-MS/MS methods to quantify hormones such as pregnenolone, 17α-hydroxypregnenolone, and cortisone in patient serum. These hormones have been shown to serve as biomarkers of pain and as indicators of abnormal hormone production.1,2 Cerilliant provides innovative solution-based reference standards for use in a variety of analytical applications ranging from clinical and diagnostic testing, toxicology, and therapeutic drug monitoring to emerging applications in endocrinology, clinical chemistry and pain management. Cerilliant’s comprehensive listing includes parent drug, metabolite, and internal standard Certified Spiking Solutions® for clinical applications involving steroids and hormones, catecholamines, vitamins including 25-hydroxyvitamin D, cardiac drugs, antidepressants, antifungals, pain management drugs and immunosuppressants.